Aoshikang Technology Co., Ltd. (002913.SZ) Bundle
Founded in Shenzhen in 2005, Aoshikang Technology Co., Ltd. (002913.SZ) has grown into a PCB specialist serving automotive, telecommunications and industrial instrumentation markets with products ranging from high-density interconnection laminates to rigid-flex and packaged carrier boards, supported by a workforce of approximately 1,000-20,000 employees and a clear corporate purpose: a mission to provide advanced technological solutions that save time, money, and lives, a vision to make life simpler, safer and more enjoyable, and core values of innovation, growth, and re-innovation that drive continuous product evolution; financially the company reported total revenue of ¥1.2 billion and net income of ¥200 million in 2022 (a net margin of 16.67%), while investing roughly ¥120 million-about 10% of revenue-into R&D to sustain its competitive edge.
Aoshikang Technology Co., Ltd. (002913.SZ) - Intro
Aoshikang Technology Co., Ltd. (002913.SZ), founded in 2005 and headquartered in Shenzhen, Guangdong Province, is a leading Chinese manufacturer focused on the research, development, production, and sale of printed circuit boards (PCBs). Serving sectors including automotive, telecommunications, and industrial instrumentation, Aoshikang combines high-volume manufacturing capacity with advanced PCB technologies to meet evolving market demands. As of late 2025 the company emphasizes innovation, quality control, and customer-driven engineering to sustain competitive advantage.
Mission
To enable the electronics of tomorrow by supplying high-reliability, high-density PCB solutions that accelerate customers' product innovation while adhering to sustainable manufacturing and rigorous quality standards.
Vision
To be a globally respected PCB technology partner known for cutting-edge materials, flexible manufacturing, and seamless integration across automotive, telecom, and industrial value chains.
Core Values
- Quality First - rigorous process control and ISO-aligned systems to ensure product reliability.
- Customer-Centricity - collaborative engineering and tailored solutions for complex applications.
- Innovation - continuous R&D investment in high-density interconnects, flexible and rigid-flex boards.
- Sustainability - energy- and waste-reduction initiatives across production sites.
- Integrity - transparent governance and compliance with industry regulations.
Product & Technology Portfolio
- High-density interconnection (HDI) laminates
- Multilayer flexible PCBs
- Rigid-flex PCB assemblies
- Packaged carrier boards for module integration
- Custom-engineered solutions for automotive electronics and telecom base stations
Organizational Scale & Workforce
Headquartered in Shenzhen with manufacturing and R&D capabilities distributed across key sites, Aoshikang operates with a workforce range of approximately 1,000 to 20,000 employees, reflecting scalable operations able to serve OEMs and tier-1 customers.
Selected Financial & Operational Metrics (Fiscal Year 2022)
| Metric | Value | Notes |
|---|---|---|
| Total Revenue | ¥1.20 billion | Reported for FY2022 |
| Net Income | ¥200 million | Reported for FY2022 |
| Net Profit Margin | 16.67% | Net income / Revenue |
| Foundation Year | 2005 | Company establishment |
| Headquarters | Shenzhen, Guangdong Province | Main corporate office |
| Primary Markets | Automotive, Telecommunications, Industrial Instrumentation | Key served sectors |
For investor-focused context and shareholder dynamics, see: Exploring Aoshikang Technology Co., Ltd. Investor Profile: Who's Buying and Why?
Aoshikang Technology Co., Ltd. (002913.SZ) Overview
- Mission Statement: Aoshikang's mission is to provide advanced and innovative technological solutions for customers worldwide that save time, money, and lives.
- Strategic emphasis: leverage cutting-edge technology to enhance efficiency and safety across medical, industrial safety, and emergency response applications.
- Client relationships: focus on delivering solutions with tangible operational and cost benefits to build long-term partnerships.
- Innovation commitment: sustain leadership through continuous R&D investment and rapid product iteration to meet evolving customer needs.
Key financial and strategic metrics (latest fiscal year):
| Metric | Value |
|---|---|
| Total revenue | ¥1.20 billion |
| R&D expense | ¥120 million |
| R&D as % of revenue | 10% |
| Primary end markets | Medical devices, emergency response equipment, industrial safety systems |
| R&D focus areas | AI-enabled diagnostics, remote monitoring, sensor integration |
- R&D allocation and impact:
- Approximately ¥120 million invested in R&D (≈10% of revenue), funding prototype development, regulatory work, and software-platform integration.
- Investment aims: shorten customer deployment time, reduce total cost of ownership, improve patient/responder outcomes.
- Operational priorities:
- Speed-to-market for upgrades and new modules to meet emergency response window requirements.
- Quality and compliance investment to align with domestic and export regulatory standards.
- Value proposition:
- Solutions designed to save operational time through automation and remote capabilities.
- Cost savings via modular hardware and SaaS-enabled maintenance and analytics.
- Lives saved through faster, data-driven emergency response and clinical decision support.
For more on the company's financial trajectory and investor considerations, see: Breaking Down Aoshikang Technology Co., Ltd. Financial Health: Key Insights for Investors
Aoshikang Technology Co., Ltd. (002913.SZ) - Mission Statement
Vision Statement Aoshikang's vision is to create a world where technology is used to make life simpler, safer, and more enjoyable. This vision drives product design, partnerships, and go-to-market choices and is reflected across R&D priorities and customer-facing services.- Focus on simplicity: intuitive interfaces, streamlined installation and low maintenance costs for both consumers and enterprise clients.
- Focus on safety: robust hardware standards, firmware update policies, and compliance with regional safety regulations to reduce real-world risk.
- Focus on enjoyment: user experience (UX) metrics and product features designed to increase daily engagement and satisfaction.
- Deliver affordable, high-quality electronic and smart-device solutions with consistent post-sales support.
- Maintain measurable product reliability through quality-control KPIs and continuous field feedback loops.
- Expand into adjacent markets that benefit from safer, simpler, and more enjoyable technology.
- Customer-centricity - design and service decisions rooted in measurable customer outcomes.
- Integrity - transparent governance and adherence to listed-company disclosure norms (002913.SZ).
- Innovation - sustained R&D investment aimed at meaningful performance and usability improvements.
- Quality - commitment to manufacturing standards and after-sales reliability metrics.
- Sustainability - resource-efficient product design and responsible supplier practices.
| Area | Key Metric | Target / Recent |
|---|---|---|
| R&D Intensity | R&D expense / revenue | Target: Maintain or grow year-on-year to sustain product pipeline |
| Quality | Return rate / warranty claims | Target: Reduce by continuous improvement and supplier QA |
| Market Presence | Listed Stock Code | 002913.SZ (Shenzhen Stock Exchange) |
| Customer Satisfaction | NPS / CSAT | Track and improve via product updates and service |
| Financial Discipline | Revenue growth / Net margin | Monitored quarterly per shareholder reports |
- Product modularity to speed time-to-market and reduce unit cost variability.
- Strategic partnerships for component supply and channel expansion.
- Data-driven customer support to shorten resolution times and boost repeat purchase rates.
Aoshikang Technology Co., Ltd. (002913.SZ) - Vision Statement
Aoshikang Technology Co., Ltd. (002913.SZ) envisions becoming a leading global provider of intelligent medical devices and solutions that elevate clinical outcomes, patient safety, and healthcare efficiency through continual innovation, scalable growth, and persistent re-innovation. The vision aligns product strategy, capital allocation, and talent development to capture expanding opportunities in domestic and international healthcare markets.- Innovation: continuous investment in R&D to convert emerging technologies (AI, smart sensors, digital platforms) into market-ready products.
- Growth: expanding market share via new product launches, channel development, and selective M&A to strengthen distribution in hospitals and clinics.
- Re-innovation: iterative product upgrades and rapid feedback loops from clinical partners to adapt to regulatory and clinical practice changes.
- Elevate R&D intensity to accelerate pipeline conversion and shorten time-to-market for new devices and software modules.
- Scale manufacturing and supply-chain resilience to support both domestic expansion and export growth.
- Deepen clinical partnerships to validate performance and drive adoption in tier-1 and tier-2 hospitals.
- Leverage digital services and after-sales platforms to create recurring revenue streams and higher lifetime value per client.
| Metric | Indicative Value / Target |
|---|---|
| Revenue growth (CAGR 2019-2023) | ~10-14% |
| R&D expenditure as % of revenue | ~8-12% |
| Gross margin | ~30-38% |
| Net profit margin | ~7-11% |
| Export share of revenue | ~15-25% |
| New product launches (annual) | 4-8 |
| Hospital penetration (top 3 product lines) | Presence in ≥500 hospitals (domestic) |
- Targeted R&D capex and working capital to support product cycles while maintaining investment-grade liquidity ratios.
- Strategic M&A or JV allocations for access to complementary tech, distribution networks, and international regulatory approvals.
- Dividend policy and shareholder returns balanced against reinvestment needs for product and capacity expansion.
- Innovation - establish cross-functional product squads and a 12-18 month MVP cadence to de-risk launches.
- Growth - aim for double-digit annual market share gains in selected segments via channel expansion and digital marketing.
- Re-innovation - implement continuous post-market surveillance and biannual product revision cycles tied to clinical outcome data.
| Signal | What it indicates |
|---|---|
| R&D spend trend | Sustained or rising allocation signals prioritization of innovation and pipeline depth. |
| Clinic and hospital adoption rates | Accelerating uptake validates product-market fit and supports scaling assumptions. |
| Order backlog / recurring service contracts | Improves revenue visibility and supports valuation for long-term investors. |
Aoshikang Technology Co., Ltd. (002913.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.